Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 202Leukemia, Lymphocytic, Chronic, B-Cell 54Recurrence 37Neoplasms, Plasma Cell 30Lymphoma, Mantle-Cell 30Lymphoma 30Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 27Leukemia 23Leukemia, Myeloid, Acute 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell, Marginal Zone 15Myelodysplastic Syndromes 13Hodgkin Disease 12Waldenstrom Macroglobulinemia 8Prostatic Neoplasms 8Lymphoma, T-Cell 8Smoldering Multiple Myeloma 7Immunoglobulin Light-chain Amyloidosis 7Neoplasms 6Melanoma 6Lymphoma, B-Cell 6Hematologic Diseases 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelomonocytic, Chronic 5Hematologic Neoplasms 5Amyloidosis 5Sezary Syndrome 4

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Mycophenolic Acid 2obinutuzumab 1nelarabine 1letermovir 1ibrutinib 1carmustine, poliferprosan 20 drug combination 1Tacrolimus 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Hematopoietic Stem Cell Transplantation 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, B-Cell × Lenalidomide × Clear all
NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡